Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||
Related Party | - | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 4 | 0 | 0 | |||||
Cash And Cash Equivalents At Carrying Value | 0 | 2 | 1 | 2 | 1 | 0 | 2 | 4 | 5 | 9 | 22 | |||||
Assets Current | ||||||||||||||||
Assets Current | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 4 | 9 | 9 | 27 | |||||
Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Held In Trust | - | - | - | - | - | - | - | - | - | - | 5 | |||||
Assets Noncurrent | ||||||||||||||||
Prepaid Expense And Other Assets Noncurrent | - | - | 2 | - | - | - | 2 | - | - | - | - | |||||
Prepaid Expense Noncurrent | - | 2 | - | - | - | - | - | - | - | - | - | |||||
Assets | 2 | 4 | 3 | 4 | 3 | 2 | 4 | 4 | 9 | 9 | 27 | |||||
Other Accounts Payable And Accrued Liabilities | - | - | - | - | - | - | - | - | - | - | 3 | |||||
Sales And Excise Tax Payable Current | - | - | - | - | - | - | - | - | - | - | 5 | |||||
Other Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Accrued Income Taxes Current | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Other Assets | ||||||||||||||||
Liabilities And Stockhold… | ||||||||||||||||
Liabilities Current | ||||||||||||||||
Accounts Payable And Other Accrued Liabilities Cur… | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Liabilities Current | 9 | 9 | 14 | 13 | 9 | 4 | 3 | 0 | 0 | 0 | 17 | |||||
Accrued Liabilities Current | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Taxes Payable Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | |||||
Derivative Liabilities Current | 1 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | |||||
Liabilities | 9 | 9 | 14 | 13 | 9 | 4 | 3 | 0 | 0 | 0 | 17 | |||||
Preferred Stock | ||||||||||||||||
Dividends Preferred Stock | ||||||||||||||||
Stockholders Equity | ||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | -7 | -5 | -10 | -10 | -6 | -2 | 1 | 4 | 8 | 9 | 10 | |||||
Additional Paid In Capital | 35 | 35 | 27 | 27 | 26 | 25 | 24 | - | 24 | 24 | 24 | |||||
Temporary Equity | ||||||||||||||||
Retained Earnings Accumulated Deficit | -42 | -39 | -37 | -36 | -32 | -26 | -23 | -20 | -16 | -15 | -14 | |||||
Treasury Stock Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -0 | - | - | |||||
Additional Paid In Capital Common Stock | - | - | - | - | - | - | - | 24 | - | - | - | |||||
Liabilities And Stockholders Equity | 2 | 4 | 3 | 4 | 3 | 2 | 4 | 4 | 9 | 9 | 27 | |||||
Series A Preferred Stock | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | |||||
Series A A Preferred Stock | - | - | - | 0 | -0 | 0 | 0 | 0 | 0 | -25 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | - | - | - | - | - | - | - | - | |||||
Preferred Stock Shares Authorized | 10 | 10 | 10 | - | - | - | - | - | - | - | - | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | - | - | - | - | - | - | - | - | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | - | - | - | - | - | - | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | |||||
Common Stock Shares Issued | 44 | 43 | 38 | 38 | 38 | 37 | 37 | 37 | 37 | 35 | 35 | |||||
Shares Outstanding | - | - | - | - | - | - | - | 37 | 37 | 35 | 35 | |||||
Treasury Stock Common Shares | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.36% | -17.23% | -35.45% | - | - | - | - | - | - | - | - | - |
| 2025 | 7.58% | -11.11% | -13.64% | 21.39% | 51.45% | 179.77% | -5.24% | -33.81% | -46.67% | 70.37% | 16.67% | 5.56% |
| 2024 | -16.76% | 12.04% | 34.26% | - | - | - | 43.81% | 47.62% | 25.00% | -26.89% | -25.21% | 0.34% |
| 2023 | - | - | - | -3.70% | 6.48% | -7.41% | -7.35% | -9.56% | -14.71% | - | - | - |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Estrella Immunopharma, Inc. (ESLA) — SEC Financial Statements & Analysis
Estrella Immunopharma, Inc. (ESLA) is a biological products, (no diagnostic substances) company. Estrella Immunopharma, Inc. trades on Nasdaq as: ESLA, ESLAW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Estrella Immunopharma, Inc. reported a Debt-to-Equity ratio of -1.25x, a Price-to-Book (P/B) ratio of -6.02x (TTM), at a market cap of $44.72M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.25x
- P/B TTM
- -6.02x
- Market Cap
- $44.72M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Estrella Immunopharma, Inc. in?
Estrella Immunopharma, Inc. (ESLA) operates in the Biological Products, (No Diagnostic Substances) industry.
What is ESLA's market cap?
Estrella Immunopharma, Inc. (ESLA) has a market capitalization of $44.72M as of 2026-06-30.
What exchange does ESLA trade on?
Estrella Immunopharma, Inc. (ESLA) trades on the Nasdaq.